Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate

Dermatology

Volumn 211, Issue 3, 2005, Pages 256-263

  Van De Kerkhof, P ^a   Griffiths, C E M ^b   Christophers, E ^c   Lebwohl, M ^d   Krueger, G G ^e  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF KIEL   (Germany)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Alefacept; Phototherapy; Psoriasis; Systemic therapy

Indexed keywords

ALEFACEPT; CYCLOSPORIN; METHOTREXATE; PSORALEN; RETINOID;

ADULT; ANAMNESIS; ARTICLE; BACKACHE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; INFECTION; INJURY; MAJOR CLINICAL STUDY; MALE; PAIN; PHARYNGITIS; PHOTOTHERAPY; PRIORITY JOURNAL; PRURITUS; PSORIASIS; QUALITY OF LIFE; RHINITIS; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; VIRUS INFECTION;

ANTI-INFLAMMATORY AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 26244438533     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087020     Document Type: Article

References (24)

1. Christophers E: Psoriasis - Epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314-320.
2. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM: Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-407.
3. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T: The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-284.
4. Koo J, Lebwohl M: Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999;41:51-59.
5. Lebwohl M, Ali S: Treatment of psoriasis. 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001;45:487-498.
6. Lebwohl M, Ali S: Treatment of psoriasis. 2. Systemic therapies. J Am Acad Dermatol 2001;45:649-661.
7. Bos JD, De Rie MA: The pathogenesis of psoriasis: Immunological facts and speculations. Immunol Today 1999;20:40-46.
8. Friedrich M, Krammig S, Henze M, Docke WD, Sterry W, Asadullah K: Flow cytometric characterization of lesional T cells in psoriasis: Intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Dermatol Res 2000;292:519-521.
9. Lowes MA, Lew W, Krueger JG: Current concepts in the immunopathogenesis of psoriasis. Dermatol Clin 2004;22:349-369.
10. Prinz JC: The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003;17:257-270.
11. Gottlieb AB, Bos JD: Recombinantly engineered human proteins: Transforming the treatment of psoriasis. Clin Immunol 2002;105:105-116.
12. Mehlis S, Gordon KB: From laboratory to clinic: Rationale for biologic therapy. Dermatol Clin 2004;22:371-377.
13. Miller GT, Hochman PS, Meier W, Tizard R, Bixlar SA, Rosa MD, Wallner BP: Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 1993;178:211-222.
14. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS: Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses: Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 1994;152:2753-2767.
15. Ellis CN, Krueger GG, for the Alefacept Clinical Study Group: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-255.
16. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN, for the Alefacept Clinical Study Group: A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002;47:821-833.
17. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE, for the Alefacept Clinical Study Group: An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719-727.
18. Fredriksson T, Pettersson U: Severe psoriasis - Oral therapy with a new retinoid. Dermatologica 1978;157:238-244.
19. Finlay AY, Kahn GK: Dermatology Life Quality Index (DLQI) - A simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-216.
20. Finlay AY, Salek MS, Haney J, for the Alefacept Clinical Study Group: Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 2003;206:307-315.
21. Feldman SR, Menter A, Koo JY: Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 2004;150:317-326.
22. Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, De La Brassinne M, Ferrandiz C, Griffiths C, Katsambas A, Kragballe K, Lynde C, Menter A, Ortonne JP, Papp K, Prinz J, Rzany B, Ronnevig J, Saurat JH, Stahle M, Stengel FM, Van de Kerkhof P, Voorhees J: Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004;151(suppl 69):3-17.
23. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG: A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004;50:859-866.
24. Callen JP, Krueger GG, Lebwohl M, McBurney EI, Mease P, Menter A, Paller AS, Pariser DM, Weinblatt M, Zimmerman G: AAD consensus statement on psoriasis therapies. J Am Acad Dermatol 2003;49:897-899.